UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 26, 2019
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: 781 -848-7100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Securities registered pursuant to Section 12(b) of the Act: | ||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
Emerging Growth Company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
Item 1.01 Entry into a Material Definitive Agreement.
On August 26, 2019, Haemonetics Corporation (the “Company”) entered into a lease (the “Lease”) with HRP Wood Road, LLC (“Landlord”) that provides for a leaseback of the Company's current headquarters located at 400 Wood Road and 355 Wood Road, Braintree, MA (the “Premises”) on a rent-free basis through December 31, 2019. The Lease, which the Company and Landlord entered into concurrently with the completion of the Company's $15.5 million sale of the Premises to Landlord on August 26, 2019, will allow the Company to continue operations at the Premises pending the completion of its previously-announced headquarters relocation to 125 Summer Street, Boston, MA, which is expected to occur in the fourth quarter of calendar 2019. Under the Lease, the Company has the option to extend the term of the Lease at fixed monthly rental rates from January 1, 2020 to February 29, 2020 and for up to one year thereafter if a force majeure event delays delivery of the new headquarters space. The Company will be responsible for certain operating expenses specified in the Lease and may terminate the Lease at any time upon 30 days' prior notice.
The foregoing description of the Lease does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease, a copy of which will be filed with the Company's Quarterly Report on Form 10-Q for the quarterly period ending September 28, 2019.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HAEMONETICS CORPORATION | ||||
Date: August 30, 2019 | By: | /s/ Christopher A. Simon | ||
Name: | Christopher A. Simon | |||
Title: | President and Chief Executive Officer | |||